Roman Butler Fullerton & Co. Sells 32,168 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Roman Butler Fullerton & Co. lessened its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 34.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 61,591 shares of the biotechnology company's stock after selling 32,168 shares during the period. Roman Butler Fullerton & Co.'s holdings in ADMA Biologics were worth $1,222,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics in the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics in the fourth quarter valued at approximately $51,000. Farther Finance Advisors LLC raised its stake in ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares during the period. AlphaQuest LLC bought a new stake in ADMA Biologics in the fourth quarter valued at approximately $84,000. Finally, GF Fund Management CO. LTD. bought a new stake in ADMA Biologics in the fourth quarter valued at approximately $85,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

NASDAQ:ADMA traded down $0.76 during trading hours on Thursday, reaching $18.13. 5,320,561 shares of the company were exchanged, compared to its average volume of 3,696,765. The company has a market capitalization of $4.33 billion, a P/E ratio of 21.33 and a beta of 0.47. ADMA Biologics Inc has a 1-year low of $10.21 and a 1-year high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The business has a 50 day moving average of $20.95 and a 200 day moving average of $18.83.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 EPS. Research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Buying and Selling

In related news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director now directly owns 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director now owns 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock valued at $9,644,269 over the last 90 days. 3.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several research reports. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial upped their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.25.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.